Olitrace (Sodium Molybdate Dihydrate, Zinc Chloride, Chromic Chloride, Copper Chloride, Ferrous Chloride, Mang)

Olitrace is used as a multi‑trace element supplement in clinical nutrition, supporting patients who receive parenteral nutrition.

• Premature infants: helps meet essential trace element requirements for growth and development.
• Adult patients on long‑term parenteral nutrition: maintains adequate levels of molybdenum, zinc, chromium, copper, iron and manganese.
• Post‑surgical or trauma patients: supports metabolic processes that rely on trace elements.
• Patients with malabsorption syndromes: provides trace elements that are poorly absorbed orally.
• Renal replacement therapy patients: assists in maintaining trace element balance during dialysis.

• Olitrace delivers a combination of essential trace elements directly into the bloodstream, bypassing intestinal absorption. These minerals act as cofactors for various enzymes involved in oxidative metabolism, nucleic acid synthesis, and immune function, ensuring that critical biochemical pathways operate efficiently in patients dependent on parenteral nutrition.

Olitrace may be associated with infusion‑related reactions and laboratory‑detected abnormalities.

Common Side Effects

• Mild erythema at the infusion site: transient redness that resolves without intervention.
• Low‑grade fever: temporary temperature elevation that subsides spontaneously.
• Transient increase in serum copper or zinc levels: laboratory finding without clinical symptoms.

Serious or Rare Side Effects

• Anaphylactic reaction: acute hypersensitivity requiring immediate medical management.
• Severe hypermagnesium (if formulation contains magnesium): may cause cardiac rhythm disturbances.
• Acute hemolysis: rapid destruction of red blood cells observed in rare cases.
• Metabolic acidosis: significant pH imbalance requiring corrective therapy.

When using Olitrace, clinicians should assess trace element status and monitor laboratory values regularly.

• Assess baseline trace element levels: obtain serum concentrations before initiating therapy.
• Monitor serum concentrations: repeat testing weekly or as clinically indicated.
• Adjust dosage in renal impairment: reduce or space infusions based on renal function.
• Avoid concurrent high‑dose oral trace supplements: risk of excess accumulation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Olitrace can interact with other medications that influence mineral balance or cause infusion reactions.

Major Interactions (Avoid)

• High‑dose intravenous iron preparations: may cause excessive iron load and oxidative stress.

Moderate Interactions (Monitor Closely)

• Chelating agents (e.g., deferoxamine): may reduce the effectiveness of administered trace elements.
• Antacids containing aluminum or magnesium: can alter absorption if oral supplements are added.
• Certain antibiotics (e.g., tetracyclines): may bind trace metals and affect their activity.
• Loop diuretics: increase urinary excretion of zinc and copper, requiring closer monitoring.
• Vitamin C high‑dose infusion: enhances copper absorption, potentially leading to excess levels.